People
Jessica Ringel advises medical device and pharmaceutical manufacturers on matters involving FDA regulation. Jessica’s practice focuses on post-market safety and quality matters, including responses to FDA inspections and enforcement actions, conducting recalls, and reporting adverse events. Her practice also includes evaluating pre-market strategy and advising on FDA-compliant promotional practices for device firms. In addition, Jessica frequently conducts due diligence evaluations for life sciences manufacturers, private equity funds, and investment banks.
In 2008, Jessica graduated magna cum laude and Order of the Coif from the Georgetown University Law Center, where she served an Executive Editor for the Georgetown Law Journal. During law school, Jessica served on the board of the law center’s Equal Justice Foundation. In 2001, Jessica graduated, with distinction and Phi Beta Kappa, from Cornell University with a B.A. in Psychology. Prior to law school, Jessica was a research assistant at the Center for Interdisciplinary Brain Science Research at Stanford University, conducting neuroimaging research.
J.D., Georgetown University, magna cum laude
B.A., Cornell University, with distinction
District of Columbia
Maryland
November 15, 2022
Jessica Ringel discusses the recently reauthorized Medical Device User Fee Amendments V and the creation of the Total Product Life Cycle Advisory Program
June 22, 2022
Jessica Ringel discusses the FDA’s Center for Devices and Radiological Health’s 2022-2025 Strategic Priorities
April 26, 2022
Wallaby Medical buys Phenox for 500 million euros
January 23, 2023
2022 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
January 9, 2023
Nearly a Century in the Making: Congress Modernizes FDA’s Regulation of Cosmetics
January 9, 2023
Not Quite the Titanic: The Food and Drug Omnibus Reform Act Rescues Some FDA Policy Initiatives
November 15, 2022
Jessica Ringel discusses the recently reauthorized Medical Device User Fee Amendments V and the creation of the Total Product Life Cycle Advisory Program
June 22, 2022
Jessica Ringel discusses the FDA’s Center for Devices and Radiological Health’s 2022-2025 Strategic Priorities
April 26, 2022
Wallaby Medical buys Phenox for 500 million euros
January 23, 2023
2022 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
January 9, 2023
Nearly a Century in the Making: Congress Modernizes FDA’s Regulation of Cosmetics
January 9, 2023
Not Quite the Titanic: The Food and Drug Omnibus Reform Act Rescues Some FDA Policy Initiatives
November 15, 2022
Jessica Ringel discusses the recently reauthorized Medical Device User Fee Amendments V and the creation of the Total Product Life Cycle Advisory Program
June 22, 2022
Jessica Ringel discusses the FDA’s Center for Devices and Radiological Health’s 2022-2025 Strategic Priorities
April 26, 2022
Wallaby Medical buys Phenox for 500 million euros
J.D., Georgetown University, magna cum laude
B.A., Cornell University, with distinction
District of Columbia
Maryland